Indobufen

DB12545InvestigationalSmall molecule

Indobufen is a reversible platelet aggregation inhibitor used to prevent coronary and peripheral artery occlusion. Indobufen has been used in trials studying the supportive care and prevention of Atrial Fibrillation.

Mechanism: Pharmacologically active on Prostaglandin G/H synthase 1
Curator reviewed
Formula / weight: C₁₈H₁₇NO₃ · 295.338 g/mol (avg)

Resolves to

Compound

UNII6T9949G4LZCAS63610-08-2ChEMBLCHEMBL1765292ChEBI135239PubChem107641

Clinical / RWD

RxNorm27518ATCB01AC10

Structure

InChIKeyAYDXAULLCROVIT-UHFFFAOYSA-NSMILESCCC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O

Targets

P23219PTGS1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,513Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

6ContraindicationsEach with its own population and attribute set

24Marketed productsAcross 1 country and 17 labellers

1ATC codeIncluding every combination product, plus 19 drug categories

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Indobufen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account